Papers
4
Total Citations
65
H-Index
3
About
John Cursio is a leading clinical researcher in head and neck oncology, with a focused expertise in human papillomavirus-positive oropharyngeal cancer (HPV+ OPC). His work centers on pioneering neoadjuvant immunotherapy and response-adaptive treatment strategies designed to de-escalate therapy and reduce toxicity without compromising survival. Cursio’s most influential contribution is his 2024 study on neoadjuvant nivolumab plus chemotherapy followed by response-adaptive therapy for HPV+ OPC, which has garnered 45 citations and helped define the role of immune checkpoint inhibitors in curative settings. He further advanced the field with the TARGET-HPV trial, evaluating neoadjuvant HB-200 immunotherapy combined with response-stratified de-intensification, and has explored circulating tumor HPV DNA as a noninvasive biomarker for treatment selection. His pooled analysis of functional and survival outcomes in response-adaptive de-escalation reinforces the safety and efficacy of these approaches. With over 65 total citations and multiple high-impact publications in 2024–2025, Cursio is at the forefront of translating immunotherapy and biomarker-driven strategies into less toxic, personalized care for patients with HPV-associated oropharyngeal cancer.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4